Eagle Pharmaceutical (EGRX) 37.48 $EGRX IMPORTANT

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 11:20 AM

Eagle Pharmaceutical (EGRX) 37.48 $EGRX

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period"

, are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline.
EGRX: 37.48 (-1.92)

INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws.
EGRX: 37.48 (-1.92)

EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 37.48 (-1.92)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 37.48 (-1.92)

Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.42 (-0.08), HCP: 34.52 (+0.41), UNIS: 3.02 (-0.18), CBL: 9.79 (+0.05), INFI: 1.33 (+0.03), EGRX: 37.48 (-1.92), NVCN: 0.50 (-0.05)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 37.48 (-1.92)

Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 37.00 (-0.03), CBL: 9.79 (+0.05), TRXC: 1.34 (-0.05), EGRX: 37.48 (-1.92), NVCN: 0.50 (-0.05)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
EGRX: 37.48 (-1.92)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 37.48 (-1.92)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Eagle Pharmaceuticals Inc. and Advises Investors With Losses to Contact the Firm
BusinessWire - Wed Jun 08, 2:39PM CDT
Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle" or the "Company"

(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 37.48 (-1.92)

EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Alerts Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors to Securities Class Action and August 1, 2016 Lead Plaintiff Deadline
GlobeNewswire - Tue Jun 07, 7:30AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 37.48 (-1.92)

INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Eagle Pharmaceuticals Inc. and Advises Investors to Contact the Firm
BusinessWire - Mon Jun 06, 8:34PM CDT
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"

(Nasdaq: EGRX). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
EGRX: 37.48 (-1.92)

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
PR Newswire - Mon Jun 06, 6:15PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the District of New Jersey on behalf of purchasers of Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ: EGRX) common stock during the period between February 23, 2016 and March 18, 2016, inclusive (the "Class Period"

.
EGRX: 37.48 (-1.92)

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc.
BusinessWire - Mon Jun 06, 5:20PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 37.48 (-1.92)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 06, 2:22PM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 37.48 (-1.92)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Eagle Pharmaceuticals, Inc. and Certain Officers - EGRX
GlobeNewswire - Fri Jun 03, 5:17PM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company"

(NASDAQ:EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
EGRX: 37.48 (-1.92)

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eagle Pharmaceuticals, Inc. (EGRX) and Encourages Investors to Contact the Firm
BusinessWire - Fri Jun 03, 3:00PM CDT
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who acquired Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 and March 18, 2016 (the "Class Period"

.
EGRX: 37.48 (-1.92)

Robbins Arroyo LLP: Eagle Pharmaceuticals, Inc. (EGRX) Misled Shareholders According to a Recently Filed Class Action
BusinessWire - Fri Jun 03, 1:39PM CDT
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Eagle Pharmaceuticals, Inc. (NASDAQGM: EGRX) in the U.S. District Court for the District of New Jersey. The complaint is brought on behalf of all purchasers of Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016, for alleged violations of the Securities Exchange Act of 1934 by Eagle Pharmaceuticals' officers and directors. Eagle Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.
EGRX: 37.48 (-1.92)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...